Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Indian Adults with Type 2 Diabetes or Obesity
NCT07438444Phase 4Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at 46 weeks. Started Feb 2026; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07438444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438444.